Evidence map›Paper›PMID 39544279›Full record

ArticleFrontiers in cellular and infection microbiology2024

Pathogen spectrum and microbiome in lower respiratory tract of patients with different pulmonary diseases based on metagenomic next-generation sequencing.

Rujun Hong, Sheng Lin, Siting Zhang, Yaxing Yi, Lanfeng Li, Haitao Yang, Zhenshan Du, Xuefang Cao, Wenjie Wu, Ruotong Ren and 2 more

Abstract read
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Co-infection withFrontiers in medicine · 2026
    Review
  5. Article
  6. Precise pathogen detection and clinical characterization of bronchiectasis.Frontiers in cellular and infection microbiology · 2025
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Rujun Hong *Department of Pulmonary and Critical Care Medicine, Fujian Provincial Hospital, Fujian Provincial Clinical Medical College, Fujian Medical University, Fuzhou, China.
Sheng Lin *Department of Pulmonary and Critical Care Medicine, Fujian Provincial Hospital, Fujian Provincial Clinical Medical College, Fujian Medical University, Fuzhou, China.
Siting Zhang *Department of Pulmonary and Critical Care Medicine, Fujian Provincial Hospital, Fujian Provincial Clinical Medical College, Fujian Medical University, Fuzhou, China.
Yaxing Yi *Medical Department, Matridx Biotechnology Co., Ltd, Hangzhou, China.
Lanfeng LiDepartment of Pulmonary and Critical Care Medicine, Fujian Provincial Hospital, Fujian Provincial Clinical Medical College, Fujian Medical University, Fuzhou, China.
Haitao YangDepartment of Pulmonary and Critical Care Medicine, Fujian Provincial Hospital, Fujian Provincial Clinical Medical College, Fujian Medical University, Fuzhou, China.
Zhenshan DuMedical Department, Matridx Biotechnology Co., Ltd, Hangzhou, China.
Xuefang CaoMedical Department, Matridx Biotechnology Co., Ltd, Hangzhou, China.
Wenjie WuMedical Department, Matridx Biotechnology Co., Ltd, Hangzhou, China.
Ruotong RenMedical Department, Matridx Biotechnology Co., Ltd, Hangzhou, China.
Xiujuan YaoDepartment of Pulmonary and Critical Care Medicine, Fujian Provincial Hospital, Fujian Provincial Clinical Medical College, Fujian Medical University, Fuzhou, China.
Baosong XieDepartment of Pulmonary and Critical Care Medicine, Fujian Provincial Hospital, Fujian Provincial Clinical Medical College, Fujian Medical University, Fuzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The homeostasis of the microbiome in lower respiratory tract is crucial in sustaining normal physiological functions of the lung. Different pulmonary diseases display varying degrees of microbiome imbalance; however, the specific variability and clinical significance of their microbiomes remain largely unexplored. Methods: In this study, we delineated the pathogen spectrum and commensal microorganisms in the lower respiratory tract of various pulmonary diseases using metagenomic sequencing. We analyzed the disparities and commonalities of the microbial features and examined their correlation with disease characteristics. Results: We observed distinct pathogen profiles and a diversity in lower airway microbiome in patients diagnosed with cancer, interstitial lung disease, bronchiectasis, common pneumonia, Nontuberculous mycobacteria (NTM) pneumonia, and severe pneumonia. Discussion: This study illustrates the utility of Metagenomic Next-generation Sequencing (mNGS) in identifying pathogens and analyzing the lower respiratory microbiome, which is important for understanding the microbiological aspect of pulmonary diseases and essential for their early and precise diagnosis.

Indexed as

High-Throughput Nucleotide SequencingMetagenomicsMicrobiotaAdultAgedBacteriaFemaleHumansLungLung DiseasesMaleMetagenomeMiddle AgedRespiratory Systemlower respiratory tractmicrobiomemNGSpathogenpulmonary disease

Identifiers

PMID39544279
PMCPMC11560916

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.